Global Oncolytic Virus Therapy Pipeline Analysis

Though still in nascent stages, Oncolytic viruses have shown immense opportunities and potential to be tapped in the future to improve the treatment of cancer and the lives of the patients. Immunotherapy, the umbrella for Oncolytic viruses would not offer cures, but survival solutions with significant importance. Also, the side effects of this therapy would be tolerable by the patients, which could thus become the most important approach to treat cancer by 2020.

The form of Oncolytic virus, which has the maximum potential in the future and is the most promising, is the reovirus. This is a non-enveloped virus with a double-stranded, segmented RNA genome which forms particles of 60 to 90 nm size. The reovirus duplicates in those cancer cells which have a common mutation called “activated Ras pathway”. The normal cells are not impacted. Thus the virus is made intrinsically tumor selective without the need for any genetic manipulation.

Download Report:

http://www.pnspharma.com/buy-report.php?reporttitle=Global-Oncolytic-Virus-Therapy-Pipeline-Analysis

“Global Oncolytic Virus Therapy Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various Oncolytic virus drugs being developed for the treatment of multiple cancers. Research report covers all the ongoing Oncolytic Virus drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Oncolytic Virus market based upon development process.

Following parameters for each Oncolytic Virus drug profile in development phase are covered in research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes

Oncolytic Virus Drug by Clinical Phase:

• Research: 1

• Preclinical: 16

• Phase-I: 6

• Phase-I/II: 5

• Phase-II: 5

• Phase-III: 2

• Registered: 1

• Discontinued: 16

For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com

Recent Publication

* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India

This release was published on openPR.